Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of aumolertinib mesylate versus gefitinib in EGFR-mutant advanced or metastatic non-small cell lung cancer
CTR20182519Phase 3Active
- Sponsor
- Allist Pharmaceuticals
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib, gefitinib in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Allist Pharmaceuticals. Started May 2019; status: active.
02
Drugs
almonertinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20182519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182519.